Advertisement

WorldCare Clinical LLC (WCC), a leading CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, announced its Endpoint Assessment Committee (EAC) services for blinded independent central review (BICR) of clinical trial data. WCC’s EAC services include expert assessments by physicians drawn from multiple therapeutic areas for comprehensive efficacy and safety reviews.
 
WCC’s strategic relationship with Massachusetts General Hospital (MGH) allows it to pull subspecialty-trained physicians from across departments for reads. From radiology and dermatology to oncology, cardiology and neurology, WCC provides blinded independent assessments by subspecialty-trained, board-certified experts, who are trained by WCC under a uniform system to maximize the precision and accuracy of data interpretation.
 
WorldCare Clinical's long-standing, cross-department relationship with MGH allows it to draw from the best independent readers. Across multiple therapeutic areas, the FDA is increasingly requiring EAC review of critical data for registration trials. This offering will enable sponsors to maximize their chances of regulatory success, by providing a more accurate and less variable interpretation of critical trial data.
 
WCC’s WorldPRO data management platform captures and consolidates all data, including images, pathology slides, pictures of skin lesions, patient feedback, and more, and organizes data for a digital central review and streamlined submission to the FDA. This unique solution facilitates fast turnaround time for reviews and presents data uniformly to multi-discipline reviewers to enable the first-ever completely digital central assessment of subjective endpoints for maximum regulatory impact. For both trials that include an imaging component and those that do not, WCC can execute a BICR of any type of clinical data.   

WorldCare Clinical LLC

Advertisement
Advertisement